TY - JOUR
T1 - Laboratory diagnosis of melioidosis
AU - Gassiep, Ian
AU - Chewapreecha, Claire
AU - Chantratita, Narisara
AU - Oakley, Tessa
AU - Mukhopadhyay, Chiranjay
AU - Lal, Piyush Behari
AU - Aucoin, David
AU - Chowdhury, Fazle Rabbi
AU - Meumann, Ella M.
AU - Currie, Bart J.
AU - Dance, David A.B.
AU - Wuthiekanun, Vanaporn
AU - Norton, Robert
N1 - Publisher Copyright:
© 2025 Gassiep et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025/12
Y1 - 2025/12
N2 - Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is an infectious disease with high rates of morbidity and mortality, which primarily affects low- and middle-income countries in South and Southeast Asia and Australia. The clinical manifestations of this disease are nonspecific and, therefore, rapid laboratory diagnosis is especially critical as appropriate management requires specific antimicrobials. This article aims to provide an overview of the current diagnostic methodologies, emerging technologies, susceptibility testing, and future perspectives for laboratory diagnosis of melioidosis. By examining conventional culture methods, mass spectrometry, antimicrobial susceptibility testing, antigen detection, molecular diagnostics, and serological assays, this article highlights the current challenges in accurately and cost-effectively diagnosing melioidosis in diverse clinical and resource-limited settings. A detailed analysis of current and future diagnostic methodologies will offer valuable insights for clinicians, researchers, and public health professionals. This review aims to influence clinical and laboratory guidelines for diagnosing melioidosis and future research directions.
AB - Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is an infectious disease with high rates of morbidity and mortality, which primarily affects low- and middle-income countries in South and Southeast Asia and Australia. The clinical manifestations of this disease are nonspecific and, therefore, rapid laboratory diagnosis is especially critical as appropriate management requires specific antimicrobials. This article aims to provide an overview of the current diagnostic methodologies, emerging technologies, susceptibility testing, and future perspectives for laboratory diagnosis of melioidosis. By examining conventional culture methods, mass spectrometry, antimicrobial susceptibility testing, antigen detection, molecular diagnostics, and serological assays, this article highlights the current challenges in accurately and cost-effectively diagnosing melioidosis in diverse clinical and resource-limited settings. A detailed analysis of current and future diagnostic methodologies will offer valuable insights for clinicians, researchers, and public health professionals. This review aims to influence clinical and laboratory guidelines for diagnosing melioidosis and future research directions.
UR - https://www.scopus.com/pages/publications/105023911806
U2 - 10.1371/journal.pntd.0013761
DO - 10.1371/journal.pntd.0013761
M3 - Review article
C2 - 41343561
AN - SCOPUS:105023911806
SN - 1935-2727
VL - 19
JO - PLoS Neglected Tropical Diseases
JF - PLoS Neglected Tropical Diseases
IS - 12
M1 - e0013761
ER -